Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cartesian Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RNAC
Nasdaq
8731
https://www.cartesiantherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cartesian Therapeutics Inc
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
- Apr 22nd, 2024 8:30 pm
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Apr 4th, 2024 11:30 am
Cartesian Therapeutics Announces New Employment Inducement Grants
- Apr 4th, 2024 11:00 am
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
- Mar 28th, 2024 8:05 pm
Cartesian Therapeutics Director Acquires 3.2% More Stock
- Mar 21st, 2024 10:49 am
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 12:00 pm
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
- Mar 6th, 2024 12:00 pm
Cartesian Therapeutics Announces New Employment Inducement Grant
- Mar 5th, 2024 12:05 pm
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
- Mar 5th, 2024 12:00 pm
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) market cap rose US$14m last week; retail investors who hold 50% profited and so did insiders
- Feb 15th, 2024 10:49 am
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
- Jan 8th, 2024 12:10 pm
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
- Jan 8th, 2024 12:00 pm
Scroll